Clinical trials: Respiratory Infection Prevention
Respiratory Syncytial Virus Infection Prevention, Tuberculosis Prevention
rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older
This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years.
- Trial name
- NCT07762014
- Testing
- Vaccination with rBCG-N-RSV, Vaccination with conventional BCG (BCG-WT)
- Where
- Greece
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Biothervax SpA
COVID-19
Study of VYD2311 for the Prevention of COVID-19
The main purpose of this study is to test an investigational drug known as VYD2311, which is being developed to lower the risk of getting COVID-19.
- Trial name
- DECLARATION (NCT07298434)
- Testing
- VYD2311-SD, VYD2311-MD
- Where
- 20 sites in United States
- Volunteers
- 1,770 people, healthy volunteers welcome
- Sponsor
- Invivyd, Inc.
COVID-19
A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19.
- Trial name
- NCT04348435
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Hope Biosciences Research Foundation
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Healthy
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2017-2018 influenza season.
- Trial name
- FluMist (NCT03158038)
- Testing
- Monovalent Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Coronavirus Disease 2019 (COVID-19)
Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled, parallel group study to assess the safety and efficacy of CSL312 administered intravenously, in combination with standard of care (SOC)…
- Trial name
- NCT04409509
- Testing
- Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
- Where
- 14 sites in United States
- Volunteers
- 124 people
- Sponsor
- CSL Behring
Influenza
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40…
- Trial name
- NCT02015494
- Testing
- VAX2012Q
- Where
- 4 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
SARS-CoV-2 Infection
To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.
This is a single blind, placebo-controlled clinical trial designed to determine the safety and tolerability of MTx-COVAB36 after a single administration in a dose escalation, dose limiting toxicity (DLT)-driven approach in…
- Trial name
- NCT05351437
- Testing
- MTx-COVAB36
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Memo Therapeutics AG
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Respiratory Syncytial Virus Infections
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
The primary objective of this study was to compare the safety and efficacy of motavizumab to palivizumab when administered monthly by intramuscular (IM) injection for the reduction of the incidence of RSV hospitalization among…
- Trial name
- NCT00129766
- Testing
- motavizumab (MEDI-524), palivizumab
- Where
- 344 sites in United States, Argentina and 22 more
- Volunteers
- 6,635 people
- Sponsor
- MedImmune LLC
Pneumonia
Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia
This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and…
- Trial name
- NCT00118781
- Testing
- iseganan hydrochloride
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- IntraBiotics Pharmaceuticals
Respiratory Tract Infections (RTI), Healthy Children
Prevention With Ismigen of RTIs in Kids
Although the efficacy of PMBL® sublingual tablets is evident to most prescribers, the clinical studies available to demonstrate the efficacy of this bacterial lysate in preventing recurrent respiratory tract infections have…
- Trial name
- PIRTIK (NCT07578012)
- Testing
- Bacterial Lysates
- Where
- 10 sites in Poland
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Lallemand Pharma AG
Prophylaxis Invasive Pneumococcal Diseases and Pneumonia
Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population
As the licensed Pneumovax 23™ vaccine is not always satisfactory in elderly subjects, the safety and the immune response of the new investigational pneumococcal protein vaccine is evaluated in healthy elderly population.
- Trial name
- NCT00307528
- Testing
- Pneumococcal vaccine GSK513026, Pneumovax 23™
- Where
- Belgium
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the…
- Trial name
- NCT01126177
- Testing
- Interferon beta 1a
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Synairgen Research Ltd.
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
COVID-19
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM]…
- Trial name
- NCT05872958
- Testing
- AZD3152
- Where
- 4 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca